After a coronary stent, most patients take aspirin for the rest of their life. The timeline that changes is how long you take aspirin alongside a second blood-thinning medication, a combination called dual antiplatelet therapy (DAPT). That dual phase typically lasts 6 to 12 months, after which aspirin continues alone as a daily low-dose pill.
The Two Phases of Antiplatelet Therapy
Stent placement works by propping open a narrowed artery, but the stent itself is a foreign object sitting inside your blood vessel. Until the artery wall heals around it, there’s a real risk of a blood clot forming on the stent’s surface. That’s why treatment comes in two distinct phases.
In the first phase, you take aspirin plus a second antiplatelet drug (commonly clopidogrel). This combination is significantly more effective at preventing clots during the critical healing window. The second phase begins once your doctor stops the second drug. At that point, you continue taking low-dose aspirin daily, typically 75 to 100 mg, as long-term protection against future heart events. International cardiology guidelines give aspirin a top-level recommendation for lifelong use in patients with a history of heart attack or stent placement.
How Long Dual Therapy Lasts
The standard recommendation is 6 to 12 months of dual therapy for most patients who receive a drug-eluting stent, which is the type used in the vast majority of procedures today. Drug-eluting stents release medication that prevents scar tissue from re-narrowing the artery, but they take longer to integrate with the vessel wall than older bare-metal stents.
Bare-metal stents, when they are used, require a minimum of just 1 month of dual therapy. However, if your stent was placed during a heart attack or another acute coronary event, guidelines recommend 12 months of dual therapy regardless of stent type, because the underlying condition itself raises clot risk.
When Dual Therapy Gets Shortened
Not everyone can safely take two blood thinners for 6 to 12 months. Patients at high bleeding risk, such as those with a history of gastrointestinal bleeding, kidney disease, or advanced age, may have their dual therapy shortened to 1 to 3 months. A large meta-analysis of over 7,200 high-bleeding-risk patients found that this shorter course reduced major bleeding events by about 66% compared to the standard duration, without increasing the rate of heart attacks, stent clots, or death. In practical terms, that translated to 21 fewer major bleeding events per 1,000 patients treated.
If you’re also taking a blood thinner for another reason, such as a condition like atrial fibrillation, the timeline shifts further. In those cases, aspirin may be stopped as early as one week after the procedure, with the other blood thinner and clopidogrel continuing together for up to 6 or 12 months depending on your clot risk.
When Dual Therapy Gets Extended
Some patients benefit from continuing dual therapy beyond 12 months. Cardiologists use a scoring tool called the DAPT score to weigh the tradeoff between preventing clots and causing bleeding. The score factors in things like whether you had a heart attack, whether you have diabetes, your age, and the size of the stent placed.
A score of 2 or higher suggests that extending dual therapy for an additional 18 months (30 months total) is likely to help more than it harms. In that group, roughly 1 in 34 patients avoids a serious clot event, while only about 1 in 272 experiences a significant bleed. For patients scoring below 2, the math flips: the bleeding risk outweighs the benefit, and stopping the second drug at 12 months is the better choice.
Low-Dose vs. Higher-Dose Aspirin
You may wonder whether you need a full-strength aspirin or the smaller “baby aspirin” dose. Research comparing 81 mg and 325 mg daily doses in stent patients found no meaningful difference in stent clot rates (1.2% vs. 1.0%). Because the lower dose carries less risk of stomach irritation and bleeding, most patients end up on 75 to 100 mg daily for long-term use.
What Happens If You Stop Too Early
Stopping the second antiplatelet drug early, after your doctor has cleared it, is different from stopping aspirin entirely. Recent evidence from a systematic review of thousands of patients found that dropping aspirin after 1 to 3 months of dual therapy (while continuing the second drug alone) did not increase heart attack risk, stent clot risk, or stroke. The rates were essentially identical: 2.5% for heart attacks in both groups, 0.6% for stent clots in both groups.
However, stopping all antiplatelet therapy, both aspirin and the second drug, during the early months after stenting is a different situation. The risk of stent thrombosis rises markedly when all antiplatelet coverage is removed within the first 6 months after a drug-eluting stent (or the first month after a bare-metal stent). Stent thrombosis is a medical emergency that frequently causes a heart attack, so any planned interruption during this window needs careful coordination with your cardiologist.
Managing Aspirin Around Surgery
If you need non-cardiac surgery after receiving a stent, timing matters. Elective procedures are generally postponed until the minimum dual therapy period is complete. When aspirin does need to be paused for a procedure, the typical recommendation is to stop it 5 to 10 days before surgery to allow your platelets to recover normal clotting function. Your surgical team and cardiologist will coordinate the safest window for this interruption, balancing surgical bleeding risk against stent clot risk.
Aspirin Alternatives
For patients who can’t tolerate aspirin due to allergy or serious gastrointestinal side effects, clopidogrel is the standard alternative for long-term use. Aspirin remains the first-line choice in most guidelines, and in clinical practice about 72% of patients end up on aspirin as their long-term single agent. But clopidogrel performs the same protective role and is a well-established backup. Recent European guidelines from 2024 have actually elevated clopidogrel’s recommendation level, giving it a top-tier rating for long-term monotherapy in patients with stable coronary disease.